Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
By Ben Glickman
Roche Group-member Genentech said Thursday it had received regulatory approval for its treatment for patients with an early-stage form of lung cancer.
The South San Francisco, Calif.-based company said that the U.S. Food and Drug Administration had approved Alecensa in treating patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who have already had tumor resection.
Alecensa is currently approved as a first- and second-line treatment for ALK-positive metastatic non-small cell lung cancer, the company said. In February, Roche reported U.S. sales of Alecensa of 467 million Swiss francs ($511.8 million).
The company said the approval was based on results from a Phase 3 study, which showed that Alecensa reduced risk of disease recurrence or death by 76%, as compared with platinum-based chemotherapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 18, 2024 18:03 ET (22:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations